InspireMD (NYSE:NSPR) Receives New Coverage from Analysts at StockNews.com

Investment analysts at StockNews.com began coverage on shares of InspireMD (NYSE:NSPR) in a report released on Thursday. The firm set a “sell” rating on the stock.

InspireMD Stock Performance

Shares of NYSE NSPR opened at $2.49 on Thursday. The stock has a market cap of $62.13 million, a PE ratio of -3.28 and a beta of 0.95. The business has a fifty day moving average of $2.37 and a two-hundred day moving average of $2.50. InspireMD has a 52-week low of $1.81 and a 52-week high of $3.85.

InspireMD (NYSE:NSPR) last released its quarterly earnings results on Tuesday, May 14th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.06). InspireMD had a negative net margin of 350.35% and a negative return on equity of 55.12%. The business had revenue of $1.51 million during the quarter, compared to the consensus estimate of $1.38 million. During the same period in the prior year, the firm earned ($0.53) earnings per share. Analysts predict that InspireMD will post -0.82 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in InspireMD stock. Mesirow Financial Investment Management Inc. purchased a new stake in InspireMD, Inc. (NYSE:NSPR) in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 30,000 shares of the company’s stock, valued at approximately $71,000. Mesirow Financial Investment Management Inc. owned about 0.13% of InspireMD as of its most recent SEC filing. 44.78% of the stock is currently owned by institutional investors and hedge funds.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.